Get the Stockscreener App
33.11
3.34%
1.07
After Hours:
33.00
-0.11
-0.33%
Apogee Therapeutics Inc stock is traded at $33.11, with a volume of 347.96K.
It is up +3.34% in the last 24 hours and down -17.94% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$32.04
Open:
$32.08
24h Volume:
347.96K
Relative Volume:
0.53
Market Cap:
$1.93B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-12.02
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+10.59%
1M Performance:
-17.94%
6M Performance:
-41.12%
1Y Performance:
-35.71%
1-Day Range:
$31.60
$33.38
1-Week Range:
$28.60
$34.23
52-Week Range:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
33.11 | 1.93B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Geode Capital Management LLC Has $36.98 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics: Engineering Biologic Dominance (NASDAQ:APGE) - Seeking Alpha
Vanguard Group Inc. Sells 29,445 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Commonwealth Equity Services LLC Buys Shares of 4,906 Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
KLP Kapitalforvaltning AS Acquires New Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics stock hits 52-week low at $29.02 By Investing.com - Investing.com Canada
Insider Purchases Worth US$990.8k See Losses As Apogee Therapeutics Market Value Drops To US$1.9b - simplywall.st
Corebridge Financial Inc. Cuts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics’ chief medical officer sells $139,801 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics’ chief medical officer sells $139,801 in stock - Investing.com Australia
Teacher Retirement System of Texas Purchases 1,848 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17 - The AM Reporter
Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
(APGE) Trading Advice - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
12 Best IPO Stocks to Buy in 2025 - Insider Monkey
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World
Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading Up 4.5%What's Next? - MarketBeat
Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com
Apogee Therapeutics initiated with a Buy at Citi - TipRanks
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock - Investing.com
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com India
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
Why Has Apogee Therapeutics Surged 9%? - timothysykes.com
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):